Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. | LitMetric
Amnion and chorion allografts have shown great promise in healing diabetic foot ulcers (DFUs). Results from an interim analysis of 40 patients have demonstrated the accelerated healing ability of a novel aseptically processed, dehydrated human amnion and chorion allograft (dHACA). The goal of this study was to report on the full trial results of 80 patients where dHACA was compared with standard of care (SOC) in achieving wound closure in non-healing DFUs. After a 2-week screening period, during which patients with DFUs were unsuccessfully treated with SOC, patients were randomised to either SOC alone or SOC with dHACA applied weekly for up to 12 weeks. At 12 weeks, 85% (34/40) of the dHACA-treated DFUs healed, compared with 33% (13/40) treated with SOC alone. Mean time to heal within 12 weeks was significantly faster for the dHACA- treated group compared with SOC, 37 days vs 67 days in the SOC group (P = .000006). Mean number of grafts used per healed wound during the same time period was 4.0, and mean cost of the tissue to heal a DFU was $1771. The authors concluded that aseptically processed dHACA heals DFUs significantly faster than SOC at 12 weeks.
Objectives Wound dehiscence is defined as the partial or complete separation of the layers of a surgical wound. Wound dehiscence and infections are of significant concern in the field of surgery as they can lead to a range of complications, including infection, delayed healing, increased healthcare costs, and patient discomfort. For patients at high risk of sternal wound dehiscence and infection, optimization of wound closure is critical.
The majority of the time hematopoietic progenitor cells (HPC) are collected through leukapheresis, where anticoagulants are necessary to prevent clotting of the apheresis circuit and HPC product. Although clotting of the product is a possible rare complication surrounding the HPC cryopreservation process, there have been no reports of clotting of fresh HPC product after collection. We report a case of progressive clotting of a fresh matched unrelated donor HPC product.
Background: Extended-spectrum β-lactamase and carbapenemase-producing are an increasing problem for patients today. Data on clinical samples for ESBL and carbapenemase-producing for surgical site infection patients in developing countries are limited, including Ethiopia, mainly due to resource constraints. Hence, this study aimed to determine the prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing among patients suspected to have surgical site infection at Hospital in Southern Ethiopia.
Urinary tract infections (UTIs) are notably more frequent in pregnant women due to hormonal changes, and if untreated, can lead to complications for both mother and fetus.
In a study of 400 patients, UTIs were identified in 26.75% of cases, with the most common bacterial uropathogens being identified and assessed for antibiotic resistance.
The results showed high susceptibility to carbapenems among gram-negative organisms and highlighted concerns about resistance to other antibiotics, particularly among staphylococci and non-albicans yeast species.
Real-world experience with an allograft adipose matrix (AAM), specifically Renuva, is highlighted through seven cases handled by nine expert cosmetic physicians in the U.S. who successfully used it.
AAM is processed donated tissue that serves as a natural filler, replacing itself with the patient’s own fat cells to restore volume.
Experts found AAM to be an effective, safe, and easy-to-use alternative to traditional fillers and fat grafting, recommending it for use on various body parts like the face and hands.
